Successful targeted injectable chemotherapy treatment for dogs could lead to human trials

November 14, 2016 By Greg Peters Daniel Aires Daniel Aires, M.D. Cody is an 11-year-old shepherd mix who loves to have his tummy rubbed and his ears scratched. Over the years, Elaine Schindel, a nurse in the radiology department at The University of Kansas Hospital, and her family have grown attached to the golden-haired stray they rescued off the streets. Elaine and Cody share a special bond well beyond the dog being her family’s beloved pet – both are cancer survivors. Coincidentally, each had their cancer knocked out by different combinations of the same cancer-fighting drug – cisplatin. Elaine is…
Read the full article

How The San Diego Zoo Is Using AI And Drones To Save Polar Bears

With Arctic sea ice disappearing, can advanced sensor technologies provide insights into an ecosystem on the brink? BY MARK WALLACE5 MINUTE READ Few things are more important to polar bears than ice, which provides the Arctic carnivores with food, migration routes, and places to bear their young. But over the last four decades, there has been less and less Arctic sea ice available, and the summer period of ice melt has grown longer, making survival more difficult for animals who currently number only about 25,000 around the world. To track the impact of changes to the Arctic ice, San Diego…
Read the full article

KCK start-up looking to tap $14B ADHD drug market

AUGUST 18, 2017 10:34 AM Experts on attention deficit hyperactivity disorder, or ADHD, are converging on Kansas City this weekend to meet with a Kansas native who has returned from the East Coast looking to build a drug company that can tap into a $14 billion market for treating the condition. Shane Schaffer, the CEO of Cingulate Therapeutics, said this weekend’s meeting of the company’s seven-member scientific advisory board will include experts from the United States, Canada and Scotland. “We’re definitely excited to bring these people into Kansas City and most of them have never been here before,” Schaffer said….
Read the full article

Cingulate Therapeutics Announces Expansion to Accommodate Growth

Kansas City, KS – (June 15, 2017) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of its Kansas City headquarters. Cingulate previously had offices at the University of Kansas Bioscience and Technology Business Center in Kansas City, KS. The move is intended to accommodate Cingulate’s growth in transition into a clinical stage development company. Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 and CTX-1302, for the treatment of Attention Deficit/Hyperactivity Disorder…
Read the full article

Cingulate Therapeutics Initiates First Human Clinical Trial

Dosing Underway in Proof of Concept Trial for CTX-1301 Kansas City, KS – (May 31, 2017) – Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), is proud to announce its transition to a clinical stage development company with the initiation of dosing in its Proof of Concept Trial for CTX-1301, one of two (2) proprietary, first-line stimulant medications the Company is developing for the treatment of ADHD. The four-week human clinical trial of CTX-1301 is being conducted in Glasgow, Scotland by its development…
Read the full article

Next

Ready to take your technology to the masses? Let’s do business.